Bevacizumab successfully treats ROP

Article

According to a presentation at the All India Ophthalmological Society meeting, when used appropriately, bevacizumab can produce remarkable results in children with severe retinopathy of prematurity (ROP).

According to a presentation at the All India Ophthalmological Society meeting, when used appropriately, bevacizumab can produce remarkable results in children with severe retinopathy of prematurity (ROP).

Alay Banker presented results from 14 eyes of nine infants with severe ROP who had been given one injection of 0.75 mg of bevacizumab. The mean birth weight was 1,133 g and the mean gestation period was 29.2 weeks. They were treated at a mean age of 2.3 months and follow-up ranged from between three and 12 months. Eight eyes had previously undergone laser treatment and six eyes received bevacizumab as first-line treatment.

All eyes fully recovered, with rubeosis disappearing within two days of treatment. No eyes required repeat treatment or experienced complications. Dr Banker explained that the timing of the treatment is crucial as later phases of ROP have higher VEGF levels than those of early-stage patients.

Dr Banker also said that, in theory, a selective-VEGF blocker such as pegaptanib might be preferable to pan-VEGF blockers, and that studies should be conducted to evaluate this further.

Dr Banker concluded that bevacizumab may offer a good first-line treatment as it is relatively inexpensive and many Indian facilities do not have access to laser or cryotherapy treatment options.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.